drugset / Trial / NCT04390685

Prevention of Breast Cancer-related Lymphedma With Tacrolimus

NCT04390685

Phase 1/2 Unknown 60 enrolled Odense University Hospital
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Breast cancer-related lymphedema is one of the most common and feared consequences of breast cancer treatment. Tacrolimus ointment may prevent lymphedema by inhibition of CD4+T cells.

Timeline

Start
2020-02-26
Primary completion
2022-09
Completion
2022-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule Topical

Indications